Marco Alings

Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial

Salim Yusuf, Harald Darius, Hans-Christoph Diener, 2011, Annals of Internal Medicine.

Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.

Á. Avezum, B. Lewis, R. Diaz, 2015, European heart journal.

Rationale and design of the Apixaban for the Reduction of Thrombo‐Embolism in Patients With Device‐Detected Sub‐Clinical Atrial Fibrillation (ARTESiA) trial

Philippe Mabo, Christopher B. Granger, Giuseppe Boriani, 2017, American heart journal.

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

Salim Yusuf, Janice Pogue, S. Yusuf, 2010, The Lancet.